Chemistry Driven-Approach Combined with Human-Centric Discovery & Development

To date, microbiome therapeutic strategies have focused primarily on adding or subtracting bacteria. Kaleido is the first company to use a chemistry-driven approach to systematically drive functional outputs of the microbiome organ. We have built a human-centric proprietary product platform for discovery and development that we believe will enable the rapid advancement of a broad portfolio of novel product candidates, Microbiome Metabolic Therapies, or MMTs. Our approach also has the potential to be faster and more cost efficient than traditional drug development.
  • Microbiome Metabolic Therapies (MMTs)
  • Mechanisms of Action of MMTs
  • Human-Centric Discovery & Development

Using our proprietary product platform, we have created a library of more than 1,000 MMT candidates. Our MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Our initial MMT candidates are targeted glycans and our library of MMTs is rapidly growing. Our MMTs are novel, proprietary compounds that are orally administered, selectively metabolized in the gut and have limited systemic exposure. Our MMTs are also related to a class that is generally recognized as safe or GRAS. We are advancing a pipeline of MMTs in multiple therapeutic areas, click here to learn more.

The Microbiome - A Newly Discovered Organ with Largely Untapped Therapeutic Potential

The human microbiome is the community of more than 30 trillion microbes, single-cell organisms that include bacteria, viruses, archaea and fungi, which reside on and inside the human body. Over the last decade research has increased exponentially on the impact the microbiome has on human health, including cardiovascular disease, cancer, diabetes, Parkinson’s disease and allergies. This highly complex microbial ecosystem has been referred to as a “newly discovered organ.” Many other human organs command tens of billions of dollars for therapeutics that treat disease by modulating physiology. From a therapeutic perspective, the microbiome organ remains a largely untapped frontier in healthcare.

Publications and Presentations

Date Title Meeting/Publication Link
March 12, 2019 Developing a Drug Discovery Platform to Target Gut Microbiota-Associated Ammonia Production Keystone Symposia, Microbiome: Chemical Mechanisms and Biological Consequences Click here
September 18, 2018 Microbiome Metabolic Therapies (MMTs) reduce pathogen colonization in ex vivo testing of intensive care unit patient microbiomes EMBO | EMBL Symposium: The Human Microbiome Click here

Additional References

Viewing these publications requires you to leave Kaleido Biosciences’ website. Kaleido assumes no responsibility for the
information, statements or other content you may encounter on third-party websites.

Date Title Meeting/Publication Link
November 25, 2014 A perspective on the complexity of dietary fiber structures and their potential effect on the gut microbiota Journal of Molecular Biology Click here
April 24, 2013 Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk New England Journal of Medicine Click here
April 11, 2012 How glycan metabolism shapes the human gut microbiota Nature Reviews Microbiology Click here
March 11, 2006 Effect of lactulose and Saccharomyces boulardii administration on the colonic urea‐nitrogen metabolism and the bifidobacteria concentration in healthy human subjects Alimentary Pharmacology & Therapeutics Click here